Anu Agarwal, vice president of global cancer support at the American Cancer Society, outlined key barriers facing oncology ...

Nuvalent has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for neladalkib for the ...

Among patients receiving metformin, Lac-Phe levels rose and remained elevated even after hormone therapy began. However, the ...

Thomas W. Flaig, MD, discusses the 2026 NCCN Guidelines updates for bladder cancer, highlighting the role of enfortumab vedotin, pembrolizumab, and the shift toward neoadjuvant ADC therapy.

In this episode of Onc Nurse on Call, hosts Patricia Jakel, MN, RN, AOCN, and Stephanie Desrosiers, DNP, MSN, RN, AOCNS, ...

Natalia Neparidze, MD, discusses subcutaneous daratumumab safety, MRD as a clinical endpoint, and emerging therapies for ...

The FDA has granted Fast Track designation to the FRα-targeting ADC ZW191 as a potential treatment for patients with for ...

Integrating palliative care principles into oncology requires the ability to allow silence to create a space where patients ...

Vaccination: HPV vaccination remains a primary target for eliminating cervical cancer. While the WHO goal is 90% coverage, global rates hover around 25%. However, in Ethiopia, cervical cancer ...

Integrative oncology is increasingly recognized as a vital component of comprehensive cancer care, focusing on the ...

The 2026 NCCN updates represent a convergence of biological precision and patient-driven lifestyle changes. By integrating ...

Sandy Srinivas, MD, of Stanford Cancer Center, discusses the critical role of patient selection, chemo-fitness, and managing ...